The gene therapy industry has predominantly focused on rare diseases, but recently there has been a shift to prevalent diseases covering a much broader patient population. This is largely in hopes to drive down the cost of therapy as well as minimize the financial risks to therapy developers. With the current clinical trials pipeline being dominated by therapies for larger populations, the industry must recognize that our current manufacturing methods cannot efficiently produce the amount of material needed to treat on a large-scale.

The ELEVECTA^TM platform is the only truly stable producer cell line on the market to date, enabling production of AAV in an adequately scaled manufacturing process to meet the demand of treating large patient populations.

Key Takeaways:

Just fill out the form below to view the recorded webcast now.